N/A N=108 Obstructive Sleep Apnea in Pregnancy
Sleep Apnea, Obstructive · Pregnancy · Obesity, Morbid
Primary: Number of Participants With a Negative Obstructive Sleep Apnea (OSA) Home Sleep Test Result — 61 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=181 The Effects of Obesity and Obstructive Sleep Apnea on Inflammation and Heart Disease
Sleep Apnea Syndromes · Inflammation
Primary: Inflammation — -11.47; -37.45; -32.66 percentage of change in crp at week 24
N/A N=34 Positive Airway Pressure Program
Sleep Apnea, Obstructive
Primary: Participant Providing Feedback — 26 Participants
N/A N=22 Combination Therapy to Treat Sleep Apnea
Sleep Apnea, Obstructive
Primary: Model Prediction of Absence/Presence of OSA: Ventilation That Causes an Arousal From Sleep (Varousal) — 5.7; 5.2 L/min — p=0.05
N/A N=104 Lifestyle Modification Program to Treat Obstructive Sleep Apnea Patients
Obstructive Sleep Apnea
Primary: Apnea-hypopnea Index (AHI) at One Year — 35.3; 39.6 events per hour
Phase 1 N=88 Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
OSA · Sleep Apnea · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index - Crossover — 34.9; 39.6 units on a scale
N/A N=144 Evaluating the Relationship Between Sleep-Disordered Breathing and Daytime Alertness
Sleep Apnea, Obstructive
Primary: Subjective Sleepiness — 11.8; 10.2; 9.9 units on a scale
N/A N=83 The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease
Hypertension · Metabolic Disorder
Primary: Change of Daytime Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Pre-treatment and Post-treatment — -8; -3; -4; -3 mm Hg — p=<0.05
Phase 2 N=13 DAW1033B2 in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 33; 20.4 events/hour of sleep — p=0.47
Phase 2 N=11 DAW1033D in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Primary: Apnea Hypopnea Index (AHI, Events/Hour of Sleep) — 21.6; 37.9 events/hour of sleep — p=0.56
N/A N=25 The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea
Sleep Apnea
Primary: Flow Mediated Dilation — 5.7; 9.5; 7.3 percentage change of vessel diamter — p=0.02
N/A N=4,577 Incidence of Obstructive Sleep Apnea in Pregnancy
Obstructive Sleep Apnea · Pregnancy
Primary: Positive Berlin Questionnaire Indicative of Sleep Disordered Breathing — 1343; 96 participants — p=0.001
Phase 3 N=280 Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring
Sleep Apnea Syndromes
Primary: Nightly CPAP Adherence — 3.7; 3.7; 3.7; 3.2 hours per night — p=0.50
N/A N=9 Long QT Syndrome and Sleep Apnea
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
Early Phase 1 N=63 Respiratory and Autonomic Plasticity Following Intermittent Hypoxia
Sleep Apnea Syndromes
Primary: Ventilation (Aim 1) — 1.19; 1.14; 1.35; 1.16 fraction of baseline — p=0.001
N/A N=45 Obesity, Sleep Apnea, and Insulin Resistance
Insulin Sensitivity · Obstructive Sleep Apnea
Primary: Change in Apnea-hypopnea Index (AHI) Outcome Measure in Response to Pioglitazone or Placebo — 35.8; 34.4 AHI events/hour
Phase 3 N=240 Effect of Self-Management on Improving Sleep Apnea Outcomes
Sleep Apnea Syndromes
Primary: CPAP Adherence — 2.8; 3.9 hours per night — p=0.001
Phase 2 N=12 Sleep Apnea Treatment With Expiratory Resistance(Provent™)
Sleep Apnea, Obstructive
Primary: Change in AHI — 45; -15.8 events/h
N/A N=54 Diagnosis and Treatment of Sleep Apnea in the Acute Exacerbation of Heart Failure
Sleep Apnea · Heart Failure
Primary: Left Ventricular Ejection Fraction Improvement — 4.5; -.3 percent change
N/A N=62 Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality
Obstructive Sleep Apnea
Primary: Respiratory Event Index (REI) at T2 — 12.8; 21.1; 9.3; 13.1 number of events per hour — p=0.152
N/A N=15 The Effects of Trazodone on Sleep Apnea Severity
Sleep Apnea, Obstructive
Primary: Apnea-Hypopnea Index — 38.7; 28.5 events/hour
Phase 2 N=23 Using Telemedicine to Improve Veteran Sleep Apnea Care
Sleep Apnea Syndromes
Primary: Treatment Adherence — 3.4; 3.6 hours/night
N/A N=29 Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk
Sleep Apnea Syndromes
Primary: Fat Mass (% of Total Body Mass) — 40.0; 37.7; 38.7; 38.6 percentage of total body mass
Phase 3 N=23 Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management
Sleep Apnea, Obstructive · Diabetes Mellitus, Type 2
Primary: Physical Activity, Steps Walked — 5892; 6071; 6284; 6684 steps walked
Phase 3 N=169 Telemedicine Interventions for Obstructive Sleep Apnea (OSA)
Sleep Apnea
Primary: Change Over 6 Months in Epworth Sleepiness Scale Score — -0.23; -1.05; 0.43; -2.62 units on a scale
N/A N=17 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Obstructive Sleep Apnea · Resistant Hypertension · Hyperaldosteronism
Primary: Severity of Obstructive Sleep Apnea — -18.3; 7.0 events/hour
N/A N=56 Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study
Apnea, Sleep
Primary: Mean Apnea Hypopnea Index (AHI) at 6 Months Post-baseline — 9.86 No. of apneas/hypopneas per h of sleep
N/A N=169 Sleep Apnea Intervention for Cardiovascular Disease Reduction
Obstructive Sleep Apnea
Primary: Change From Baseline in 24-hour Blood Pressure at Months 6 and 12 by Pooled Arms — 1.82; 1.06; 0.59; -0.73 mmHg
Phase 3 N=1,105 Apnea Positive Pressure Long-Term Efficacy Study
Lung Diseases · Sleep Apnea Syndromes · Sleep
Primary: Effect of CPAP on Neurocognitive Function: E/F Function- SWMT-OMD — 0.035; -0.074; 0.072; 0.018 score on a scale — p=0.0074
N/A N=39 Effective Treatment of Sleep Apnea in Prediabetes to Reduce Cardiometabolic Risk
Diabetes · Sleep Apnea
Primary: Change From Baseline in Area Under the Curve (AUC) Glucose at Week 2 — -794.2; 482.7 (mg/dL)*min — p=0.03